An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).
Inclusion Criteria:
Exclusion Criteria:
Sherman Oaks, California 91403, United States
Tampa, Florida 33613, United States
Saint Charles, Missouri 63304, United States
Nashua, New Hampshire 03060, United States